The 2019 Balance Sheet and Income Statement for Enzyme Biomedical are below: Enzyme Biomedical Balance Sheet As at December 31st Enzyme Biomedical Income Statement Year Ended Dec. 31st, 2019 (in millions of Canadian Dollars) Revenue 221,600 ASSETS 2019 2018 Cost of Goods Sold 70,600 Current Assets Gross Profit 151,000 Cash 6,700 5,300 Accounts Receivable 25,300 26,900 Expenses Inventory 91,800 89,800 Total Current Assets 123,800 122,000 Salaries Expense Depreciation 27,800 4,000 Land 89,000 60,000 Utilities Expense 10,500 Property, Plant & Equipment 79,500 71,400 Interest Expense 11,600 Accumulated Amortization (26,000) (22,000) Total Expenses 53,900 Total Assets 266,300 231,400 Income Before Taxes 97,100 LIABILITIES & EQUITY LIABILITIES Income Tax Expense 29,100 Current Liabilities Accounts Payable 30,900 35,400 Net Income 68,000 Salaries Payable 30,600 28,600 Total Current Liabilities 61,500 64,000 LIABILITIES & EQUITY LIABILITIES Income Tax Expense 29,100 Current Liabilities Accounts Payable 30,900 35,400 Net Income 68,000 Salaries Payable 30,600 28,600 Total Current Liabilities 61,500 64,000 Long Term Debt 75,000 100,000 Total Liabilities 136,500 164,000 EQUITY Contributed Capital 88,300 64,700 Retained Earnings 41,500 2,700 Total Equity 129,800 67,400 Total Liabilities & Equity 266,300 231,400 Other Information: Enzyme Biomedical had no non-cash investing or financing transactions during 2019. During the year, they had no sales of land or equipment, no issuance of new debt, and no repurchase of shares. REQUIRED: 1. On the following page(s), prepare Enzyme Biodmedical's Statement of Cash Flows for the Year Ended December 31st, 2019. 2. Calculate the company's Free Cash Flow. 3. Comment on key insights the Statement of Cash Flow provides us about Enzyme Biomedical financial performance